IMMUNOGENICITY OF DNA-HSP65 VACCINE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是确定DNA-hsp65疫苗对引起结核病的细菌产生免疫反应的能力。恒河猴将只接种一种针对分枝杆菌(结核病)感染的候选疫苗。他们不会受到结核分枝杆菌的挑战。我们预计，接种疫苗的群体将表现出保护性免疫反应，主要由血液中的细胞和细胞因子(调节免疫系统细胞之间通讯的小蛋白)介导。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to determine the capacity of a DNA-hsp65 vaccine to elicit an immune response against the bacterium that causes TB. Rhesus monkeys will receive only a candidate vaccine against mycobacterial (tuberculosis) infection. They will not be challenged with M tuberculosis. We expect that the vaccinated groups will demonstrate a protective immune response mainly mediated by cells in the blood and by cytokines (small proteins that regulate communication among immune system cells).